Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30695898 | 1.00 | LIMK1 (0.30) | LIMK1 | |
| SCHEMBL31378729 | 0.85 | ADRA2A (0.33) | LIMK1 | |
| SCHEMBL16416195 | 0.82 | HDAC1 (0.30) | — | |
| SCHEMBL20614676 | 0.78 | — | — | |
| SCHEMBL2054542 | 0.78 | WNT3A (0.33) | — | |
| SCHEMBL30711991 | 0.75 | NNMT (0.48) | — | |
| SCHEMBL13336015 | 0.74 | PIK3CD (0.33) | — | |
| SCHEMBL16337222 | 0.74 | — | — | |
| SCHEMBL29954511 | 0.74 | PIK3CD (0.30) | — | |
| SCHEMBL846335 | 0.74 | MAP3K14 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240467-B1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2013-03-20 | — | — | EP | claimed |
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG | 2013-02-21 | — | — | US | claimed |
| EP-2240467-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2010-10-20 | — | — | EP | claimed |
| WO-2009089057-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INS. (US) | 2009-07-16 | — | — | WO | claimed |
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| WO-2025030163-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-02-06 | — | — | WO | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4323349-A1 | ISOINDOLINONE AMIDE COMPOUNDS USEFUL TO TREAT DISEASES ASSOCIATED WITH GSPT1 | Monte Rosa Therapeutics AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-20020019390-A1 | Imidazole and imidazoline derivatives and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-02-14 | — | — | US | disclosed |
| US-6294566-B1 | ENANTIOMORPHS REVERSE AND ADRENERGIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-09-25 | — | — | US | disclosed |
| US-6093727-A | A SELECTIVE AGONISTS FOR HUMAN ALPHA 2 RECEPTORS FOR TREATING DISORDERS AS HYPERTENSION, PAIN, GLAUCOMA, ALCOHOL AND DRUG WITHDRAWAL, ISCHEMIA, RHEUMATOID ARTHRITIS, MIGRAINE, COGNITIVE DEFICIENCY, SPASTICITY, DIARRHEA, NASAL CONGESTION | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-07-25 | — | — | US | disclosed |
| US-5866579-A | SELECTIVE AGONISTS FOR CLONED HUMAN ALPHA-2 ADRENERGIC RECEPTORS. | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0556008-B1 | Condensed imidazopyridine derivatives with psychotropic activity | SHIONOGI & CO (JP) | 1997-05-14 | — | — | EP | disclosed |
| US-5461062-A | Psychotropic agent as antianxiety agent, anesthesia antagonistic agent | SHIONOGI & CO., LTD. (JP) | 1995-10-24 | — | — | US | disclosed |
| US-5378848-A | Benzodiazepine agonist, psychotropic, antianxiety, cerebral function activator, anesthesia atagonist | SHIONOGI & CO., LTD. (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0556008-A1 | Condensed imidazopyridine derivatives with psychotropic activity | SHIONOGI & CO., LTD. (JP) | 1993-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045973-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | LIMK1 2524/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | LIMK1 3313/4885 |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | LIMK1 3313/4885 |
| US-20020019390-A1 | Imidazole and imidazoline derivatives and uses thereof | ADRB2, ADRA2C, ADRB3 | LIMK1 3766/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | LIMK1 4174/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | LIMK1 3313/4885 |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | LIMK1 2005/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | LIMK1 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.